Skip to main content
Premium Trial:

Request an Annual Quote

Anitoa Systems Gets CE-IVD Mark for Portable qPCR Instrument

NEW YORK – Anitoa Systems has received the CE-IVD mark for its Maverick portable qPCR instrument. The Sunnyvale, California-based medical device company will now be permitted to commercialize the system within the European Union and other countries that recognize the CE mark.

"We are excited to now offer laboratories in the EU and other international markets a portable solution for rapid and on-site nucleic acid [testing] to help combat diseases such as COVID-19," Zhimin Ding, CEO of Anitoa Systems, said in a statement.

The Maverick instrument enables multiplexed nucleic acid detection using proprietary complementary metal-oxide-semiconductor (CMOS) four-channel fluorescence optics, the firm said, supporting testing without the need for calibration in the field. The instrument is also paired with cloud-based software that allows for cloud storage and retrieval of data.

"We believe our portable qPCR instrument and its associated [software] solutions offer features that uniquely meet the needs of the EU and other international markets through the highly sensitive detection of key life-threatening pathogens while being extremely cost effective," Ding said. The firm previously said its instrument would cost in the range of $3,500 to $6,000, depending on the number of optical channels. 

Anitoa said it has demonstrated the Maverick system for the detection of hepatitis B and C, HIV, African Swine Flu, influenza A and B, and SARS-CoV-2. The instrument has been shown to reliably detect three copies of pathogen genome per sample, with over 10 orders of magnitude in dynamic range, according to the firm.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.